Table 1 Probabilities used in the costing models

BRCA1/BRCA2 mutation prevalence

BRCA1/BRCA2 mutation prevalence in a general population

0.890

2302

U.S.

0.5637

[36]

0.392

5384

Malaysia

[37]

0.677

1548

UK

[38]

Probability of having a family history in the general population

0.98 (0.47–1.39)

NA

UK

0.98

[39]

Probability of BRCA1/BRCA2 mutation in individuals with a family history of breast or ovary cancer

16.54

127

Greek

23.05

[40]

19.14

418

Brazil

[41]

23

133

China

[42]

24

21,401

Germany

[43]

21.50

349

Brazil

[44]

23.05

256

North Spain

[45]

BRCA1/BRCA2 mutation prevalence in breast cancer patients without a family history of breast cancer

11.06

434

Nigeria

10.47

[46]

5

266

Peru

[47]

13.43

134

Tunisia

[48]

10.76

2769

China

[49]

Probability of preventive interventions

The probability that the carrier will undergo RRM

50

306

Denmark

26.4

[50]

40

211

Manchester

[51]

35.6

407

Netherland

[52]

25.1

346

Slovenia

[53]

18

1383

Canada

[54]

21

325

Australia

[55]

The probability that a BC patient will undergo RRM

33

581

Wales

31.5

[56]

30

NA

UK

[57]

The probability that a BRCA carrier will follow up with RRSO

74

305

North California

66

[58]

58

170

New York

[59]

52

42

Korea

[60]

50

26

Netherland

[61]

The probability that a BC patient will follow up with RRSO

37

581

Wales

59.23

[56]

55

NA

UK

[39, 62]

56.7

NA

UK

[29]

66

NA

UK

[31]

Performing MRI

30.6

1134

Canada

30.6

[54]

Performing mammography

87.5

1134

Canada

87.5

[54]

Probability of side effects and other outcomes

Seroma

38.7

152

Iran

36.31

[63]

32.8

103

[64]

Breast prosthesis

87

148

74.51

[65]

57.4

108

[66]

Getting chronic disease because of oophorectomy

72 (68–76)

16,914

UK

72

[67]

Performing hormone replacement therapy

39

75

Canada

37

[68]

47

57

Netherland

[69]

30

96

Canada

[70]